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Zusammenfassung
Hintergrund: Das Programm Patienten-Compliance bei 
Anastrozoltherapie (PACT) ist eine große randomisierte Stu-
die, die evaluieren soll, ob die regelmäßige Bereitstellung 
von Informationsmaterialien (EM) die Compliance unter einer 
adjuvanten Aromataseinhibitor-Therapie bei postmenopau-
salen Patientinnen mit frühem, hormonrezeptor-positivem 
Mammakarzinom verbessern könnte. Patientinnen und Me-
thoden: PACT stellt ein großes, homogenes Patientinnenkol-
lektiv dar. Die hier dargestellte Baseline-Analyse beschreibt 
Demographie und Erstbehandlung sowie die Patientinnen-
Selbsteinschätzung in Hinsicht auf Therapie und Lebensqua-
lität. Ergebnisse: Insgesamt wurden 4923 Patientinnen an 109 
deutschen Brustzentren und Kliniken in Kooperation mit 1361 
niedergelassenen Gynäkologen und Onkologen in die Studie 
eingeschlossen. 4844 Patientinnen wurden 1:1 zu Standard-
therapie (n = 2402) bzw. Standardtherapie mit zusätzlichen 
EM (n = 2442) randomisiert. 76% der Patientinnen erhielten 
vor Studieneinschluss eine brusterhaltende Therapie und 
24% eine Mastektomie. Eine Strahlentherapie war für 85% 
der Patientinnen geplant und eine Chemotherapie für 38%. 
Wie in dieser postmenopausalen Krankenpopulation mit 
 endokrin empfindlichen Tumoren zu erwarten war, erhielten 
nur 285 Patientinnen (7%) eine neoadjuvante Chemotherapie. 
Schlussfolgerungen: Der Vergleich mit den epidemiologi-
schen Daten des Westdeutschen Brustzentrums zeigt, dass 
die Patientengruppe der PACT-Studie repräsentativ für die 
allgemeine postmenopausale Patientenpopulation ist. Dies 
legt nahe, dass die Ergebnisse der PACT-Studie sehr gut auf 
die reale Behandlungssituation in Deutschland und darüber 
hinaus übertragbar sein werden. Die Ergebnisse zur Compli-
ance in der PACT-Studie werden daher dringend erwartet.
Keywords
Breast cancer · Compliance · Aromatase inhibitors · 
 Breast-conserving surgery · Mastectomy
Summary
Background: The Patient’s Anastrozole Compliance to Ther-
apy (PACT) program is a large randomized study designed 
to assess whether the provision of educational materials 
(EM) could improve compliance with aromatase inhibitor 
therapy in postmenopausal women with early, hormone re-
ceptor-positive breast cancer. Patients and Methods: The 
PACT study presented a large, homogeneous dataset. The 
baseline analysis included patient demographics and initial 
treatments and patient perceptions about treatment and 
quality of life. Results: Overall, 4,923 patients were enrolled 
at 109 German breast cancer centers/clinics in cooperation 
with 1,361 office-based gynecologists/oncologists. 4,844 
women were randomized 1:1 to standard therapy (n = 2,402) 
or standard therapy plus EM (n = 2,442). Prior breast-con-
serving surgery and mastectomy had been received by 76% 
and 24% of the patients, respectively. Radiotherapy was 
scheduled for 85% of the patients, adjuvant chemotherapy 
for 38%. Reflecting the postmenopausal, hormone-sensitive 
nature of this population, only 285 patients (7%) had 
 received neoadjuvant chemotherapy. Conclusions: A com-
parison with epidemiological data from the West German 
Breast Center suggests that the patients in the PACT study 
are representative of a general postmenopausal early breast 
cancer population and that the findings may be applicable 
to ‘real-world’ Germany and beyond. Compliance data from 
PACT are eagerly anticipated.
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Introduction
Breast cancer is the most frequently diagnosed cancer in 
women worldwide. In 2008, 23% of the total new cancer cases 
and 14% of cancer deaths were attributable to breast cancer, 
and approximately half of all cases are thought to occur in 
 developed countries [1]. In Germany, about 71,660 new cases 
of breast cancer are diagnosed each year [2] and the overall 
breast cancer mortality rate is 24.6 per 100,000 women [2].
For postmenopausal women with hormone receptor-posi-
tive early breast cancer, adjuvant endocrine therapy is the 
 recommended treatment since it has been shown to reduce 
the risk of recurrence and to increase overall survival [3, 4]. 
Third-generation aromatase inhibitors (AIs) are widely rec-
ommended in these patients for first-line endocrine treatment 
[5] where there is node-positive disease [6] or following 
2–3 years of tamoxifen treatment [5, 7]. In the Arimidex, 
Tamoxifen, Alone or in Combination (ATAC) trial, first-line 
treatment with the non-steroidal AI anastrozole (Arimidex®, 
AstraZeneca, Wedel, Germany) was shown to be superior to 
tamoxifen treatment in terms of both efficacy and safety, at a 
median follow-up of 68 months [8]. These benefits have been 
shown to be maintained after treatment completion in an 
analysis at 10 years [9].
In order to achieve the same benefits of adjuvant endo-
crine therapy in the clinic as those observed in clinical trial 
settings, long-term adherence to treatment (at least 5 years) is 
required [10]. Robust data are not widely available concern-
ing the compliance with adjuvant endocrine therapy in breast 
cancer; however, findings from a study in the USA indicated 
that poor compliance rates were observed with endocrine 
therapy versus radiotherapy or chemotherapy [11]. While 
 limited data regarding treatment compliance with adjuvant 
endocrine therapy suggest that compliance may be an issue in 
women with breast cancer [12–14], these findings are not from 
prospective studies in real-life clinical settings. Furthermore, 
while data are available on the practice of prescribing AIs in 
Germany [15, 16], these do not accurately capture whether 
the medication was actually taken correctly.
We designed the Patient’s Anastrozole Compliance to 
Therapy (PACT) program to prospectively evaluate the ex-
tent of compliance, and potential reasons for non-compliance, 
in postmenopausal women with early breast cancer receiving 
anastrozole as initial adjuvant therapy. To our knowledge, 
Fig. 1. Study design and information about educational materials. Starter set: letter, brochures ‘Breast cancer and endocrine therapy’ and ‘Social 
information’, diary/notebook reminder stickers, pill box. Week 1: letter, brochure ‘Side effects of aromatase inhibitors’. Week 3: letter, brochure ‘Self-
reflection: a personal experience’, lip balm. Week 5: letter, brochure ‘Early recognition and treatment’, fitness band with exercise suggestions. Week 8: 
letter, brochure ‘Communication with friends and family, and your caring physician’. Week 12: letter, brochure ‘Coping with fears’, CD with relaxation 
music. Month 5: letter, brochure ‘Breast cancer and sexuality’. Month 7: letter, brochure ‘Exercise and diet’, sports towel. Month 12: letter, optional 
registration for a reminder service, handbag mirror.
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consideration of offering participation in the PACT program. The treat-
ing physician was required to follow local therapy guidelines and standard 
practice. Patient registration and informed consent were obtained follow-
ing tumor board decision, and all patients were informed about anastro-
zole prior to being told about the study.
Study Endpoints
Primary endpoints were to assess and compare the differences in compli-
ance rates and persistence rates after 12 months of adjuvant endocrine 
therapy between the standard and standard-plus-EM arms. Secondary 
endpoints were: assessment and comparison of the persistence rates and 
compliance rates with adjuvant endocrine therapy between the two arms 
after 24 months of therapy; assessment of time to treatment discontinua-
tion and reasons for treatment discontinuation; identification of factors 
influencing and correlating with the persistence and compliance rate (in-
cluding quality of life); disease-free survival after 12 and 24 months of 
adjuvant endocrine treatment and association of this clinical endpoint 
with compliance rates; and assessment of treatment tolerability and 
toxicity.
Statistical Analysis
The compliance rate was defined as the percentage of patients being 
‘compliant’ to anastrozole therapy at 12 months. Patients were classed as 
compliant if they scored 80–100% when questioned about their daily in-
take of anastrozole and if all prescription information (documented by 
the investigator) was consistently available for the individual treatment 
period. The persistence rate was defined as the percentage of patients 
PACT comprises the largest homogeneous dataset evaluating 
compliance and quality of life in endocrine-responsive early 
breast cancer. In this paper, we report the PACT study design 
and methodology and present the patient baseline data.
Patients and Methods
Aims
The primary study objective was to assess whether provision of additional 
educational materials (EM) in the form of motivational letters and infor-
mational brochures could be used to enhance compliance in postmeno-
pausal women with early breast cancer receiving anastrozole.
Patients
Patients > 18 years were eligible for inclusion in this study if they had 
confirmed hormone receptor-positive (estrogen receptor (ER) and/or 
progesterone receptor (PgR)) primary breast cancer, were postmeno-
pausal (menses > 1 year ago), had undergone bilateral oophorectomy or 
had serum follicle-stimulating hormone, luteinizing hormone and plasma 
estradiol levels in the postmenopausal range. As this was a non-interven-
tional study, the treating physician determined the postmenopausal status 
in line with the inclusion criteria. Women meeting these criteria with no 
menses for ≥ 1 year, either as a result of natural biological age or chemo-
therapy, could be included in the study if the treating physician judged 
that menses would not return. Patients had had to be scheduled by the 
investigator for adjuvant endocrine treatment with anastrozole after the 
usual treatment for breast cancer and had to have the ability to read and 
understand German. Patients were excluded if they had moderate or 
 severe hepatic dysfunction or severe renal dysfunction (creatinine clear-
ance < 20 ml/min), if they were receiving concomitant therapy known to 
affect the sex hormone status or were taking tamoxifen.
The study was performed in accordance with the Declaration of 
 Helsinki and was approved by the ethics committee of Ulm and by all ap-
propriate local ethics committees. All patients provided written informed 
consent.
Study Design
PACT is a prospective, multicenter, nationwide, randomized, open, 
 parallel-group, non-interventional study (fig. 1). Specialized clinics 
(breast centers) collaborated with office-based gynecologists or oncolo-
gists for further recruitment of patients. In total, 109 breast centers/clinics 
and 1,361 gynecological and oncological practices in Germany were active 
in recruiting and treating patients in the study (fig. 2).
Patients were randomized on a 1:1 basis to receive standard therapy 
(adjuvant endocrine therapy (anastrozole 1 mg once daily)) or standard 
therapy plus EM. The EM comprised 9 letters and brochures sent to the 
patient by mail during the first year of therapy, which were accompanied 
by gift items of low monetary value (7-day tablet box, lip care stick, fit-
ness band including exercise tips, CD with relaxation music, towel, pocket 
mirror). The materials were designed with the aim of motivating the par-
ticipants to take their medication on a regular basis, by discussing issues 
likely to be of particular relevance at specific points in time during 
 therapy. The materials were developed with the assistance of 5 patient 
advocates who had all been affected by breast cancer and were active in 
the sphere of patient advocacy. These patrons were authors and a com-
munications trainer, and/or were involved with national breast cancer 
foundations and societies.
During the study, the patients were permitted to receive any further 
investigations and treatments deemed necessary by their investigators ac-
cording to current standards of care. As this was an in-practice evaluation 
study, the decision to treat with anastrozole was required to be taken, and 
documented, independently (tumor board or treating physician) prior to 
Fig. 2. Distribution of PACT study centers (n = 109) throughout Germany.
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19% were widowed and 8% were divorced. The majority of 
the patients had children (79%), with 2 children being most 
frequent (35%) and 1 child being the next most frequent 
(25%). The highest school qualifications reported by most 
 patients were Mittlere Reife (awarded after 10 years of 
 schooling; 48%) and Hauptschulabschluss (awarded after 
9 years of schooling; 28%).
At baseline, patients were asked about the number of other 
tablets they were taking (not including anastrozole). Data are 
available for 60% of all patients. Only 2% of all patients 
 reported taking no concomitant medication. Most patients 
 reported taking 1–2 (28% of patients) or 3–5 additional 
 tablets per day (19% of patients), while approximately 10% 
of the patients reported taking more than 5 tablets per day. 
Concomitant conditions were widely reported within this 
 population (n = 8,226, multiple answers permitted per pati-
ent). The most frequently reported conditions included: car-
diovascular disease (25%), thyroid disorders (11%), joint pain 
(7%), back pain (6%), angiopathies (‘other conditions of the 
vascular system’ excluding thromboembolism; 6%), and dia-
betes (5%).
with a persistent use of anastrozole at 12 months. A patient was classified 
as a persistent user of anastrozole when the case report form (CRF) docu-
mentation, independent of the evaluation of compliance, supported the 
intake of anastrozole during the full 12-month period. All other cases 
(e.g. premature discontinuation from study or anastrozole therapy) resul-
ted in a non-persistent classification.
The patients’ self-reported health-related quality of life and disease-
related symptoms were assessed at baseline and after 12 and 24 months, 
or at treatment termination, using the European Organization for the Re-
search and Treatment of Cancer Quality of Life C30 Core Questionnaire 
(EORTC QLQ-C30) and the EORTC Breast Cancer-Specific Quality of 
Life Questionnaire (EORTC QLQ-BR23). For the general health status 
and quality of life, the scores were from ‘1’ for ‘very poor’ to ‘7’ for ‘excel-
lent’. Social, cognitive, sexual and other functioning scales ranged from ‘1’ 
for ‘very poor’ to ‘4’ for ‘excellent’. Scores of ‘1’ were calibrated to equate 
to ‘0’ (very poor) and scores of ‘7’ for health status and quality of life and 
‘4’ for all other questions were equated to ‘100’ (excellent). Symptoms 
reported by patients were also assessed using the EORTC QLQ-C30 and 
-BR23 German questionnaires. The degree of various symptoms patients 
had experienced prior to study start was rated from 1 (absence of sym-
ptoms) to 4 (very strong symptoms). These scores were calibrated to ‘0’ 
for no symptoms and ‘100’ for very strong symptoms.
To determine the sample size of the study, the following assumptions 
were applied. Fisher’s exact test (two-sided) was selected for determina-
tion of the differences in compliance rate and persistence rate between 
the two intervention groups. By implementing Fisher’s exact test with 
a = 0.05 and assuming a compliance rate in patients receiving standard 
therapy of 50%, a sample size of 4,674 patients (2,337 patients per arm) 
was considered sufficient. This was based on the assumption that approxi-
mately 10% of all enrolled patients would discontinue anastrozole ther-
apy during the first year and would therefore not be included in the 
 intent-to-treat population.
This paper will present descriptive data from the baseline survey. The 
study is registered with ClinicalTrials.gov (NCT00555867).
Baseline Results
Patient and Tumor Characteristics
Between October 2006 and November 2008, 4,923 postmeno-
pausal women starting adjuvant treatment with anastrozole 
were recruited to the PACT program at 109 breast cancer 
centers/clinics in cooperation with 1,361 office-based gyneco-
logists and oncologists (fig. 2). A total of 4,844 women were 
then randomized 1:1 to standard therapy (n = 2,402) or stan-
dard therapy plus EM (n = 2,442). Of these, 4,397 patients 
were evaluable for baseline characteristics (fig. 3). The treat-
ment groups were well balanced at baseline with regard to 
 patient demographics, tumor characteristics, prior therapies, 
and attitudes to therapy.
The patient demographics are shown in table 1. The me-
dian patient age in the study was 65.5 years and the majority 
of the patients had a body mass index (BMI) of either < 25 
(36.5%) or ≥ 25 to < 30 (37.8%). Almost all (95%) patients 
had an Eastern Cooperative Oncology Group (ECOG) per-
formance status of 0 or 1. The majority of the patients were 
native to Germany (78%) and were either retired or consid-
ered themselves as housewives (66%). Most patients reported 
being married and living with their partner (59%); however, Fig. 3. Patient flow in PACT study.
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Characteristic Study population,  
n (%)
Epidemiological 
 population, n (%)
Total number of patients 4,397 89,317
Age, years
Median 65.5 62
≤ 65 2,099 (47.7) 41,373 (46.3)
> 65 2,298 (52.3) 47,944 (53.7)
BMI, kg/m2
< 25 1,605 (36.5) 12,657 (14.2)
≥ 25 to < 30 1,662 (37.8) 9,819 (11.0)
≥ 30 1,102 (25.1) 6,770 (7.6)
Not disclosed 28 (0.6) 60,071 (67.3)
ECOG PS (Karnofsky scale)
0 (100%) 2,466 (56.1) 36,276 (40.6)
1 (80–90%) 1,721 (39.1) 31,361 (35.1)
≥ 2 (10–70%) 182 (4.1) 6,044 (6.8)
Not disclosed 28 (0.6) 15,636 (17.5)
Native country –
Germany 3,414 (77.6)
Eastern Europe (excluding Russia) 235 (5.3)
Western Europe (excluding Germany) 45 (1.0)
Other 703 (16.0)
Employment status –
Employed (full- or part-time) 416 (9.5)
Retired/homemaker 2,887 (65.7)
Unemployed 107 (2.4)
Certified unfit for work 557 (12.7)
Other/not disclosed 430 (9.8)
Marital status –
Divorced 368 (8.4)
Married and living with partner 2,585 (58.8)
Married and not living with partner 69 (1.6)
Single 197 (4.5)
Widowed 827 (18.8)
Not disclosed 351 (8.0)
Number of children –
0 915 (20.8)
1 1,114 (25.3)
2 1,547 (35.2)
3 543 (12.4)
≥ 4 273 (6.2)
Not disclosed 5 (0.1)
Highest school qualification –
Mittlere Reife (awarded after 10 years of schooling) 2,095 (47.7)
Hauptschulabschluss (awarded after 9 years of schooling) 1,209 (27.5)
Abitur (awarded after 13 years of schooling) 492 (11.2)
No qualification 75 (1.7)
Other 132 (3.0)
Not disclosed 394 (9.0)
Additional number of tablets per day –
0 101 (2.3)
1–2 1,243 (28.3)
3–5 836 (19.0)
6–10 376 (8.6)
> 10 79 (1.8)
Not disclosed 1,762 (40.1)
Concomitant conditions > 3%a –
Cardiovascular system 2,029 (24.7)
Thyroid disorder 904 (11.0)
Other (undisclosed) 755 (9.2)
Joint pain 533 (6.5)
Back pain 508 (6.2)
Other types of angiopathy 459 (5.6)
Diabetes 435 (5.3)
Hot flushes 380 (4.6)
Gastrointestinal symptoms 336 (4.1)
Other metabolic diseases 309 (3.8)
Thromboembolism 306 (3.7)
Osteopenia/osteoporosis 276 (3.4)
aTotal number of conditions reported = 8,226. Multiple responses permitted per patient.
BMI = Body mass index, ECOG PS = Eastern Cooperative Oncology Group performance status.
Table 1. Baseline 
demographics of  
the study popula-
tion and the German 
 epidemiological 
 patient population
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those tested) and high (3+) overexpression in 372 samples 
(8% of those  tested). Fluorescent or chromogen in-situ hybri-
dization (FISH/CISH) testing was performed on 873 tumors, 
of which 111 (12.7%) were assessed as positive. FISH/CISH 
tests were performed on 19.8% of the total patient popula-
tion, of which 2.5% were assessed as positive.
Prior Surgery, Radiotherapy and Chemotherapy
Approximately three-quarters of the total 4,397 patients had 
received breast-conserving surgery (BCS) and 24% a mastec-
tomy. Although defined as being mutually exclusive within 
the primary surgery classification, the physician responses 
showed that 57 patients received both BCS and mastectomy. 
The baseline tumor characteristics are presented in table 2; 
not all patients received all possible tests to determine the 
tumor characteristics. The majority of the tumors were 
grade 2 (n = 3,011, 66%); 42% were diagnosed as stage IA 
(T1 N0; n = 1,910). Bilateral tumors were reported in 136 pa-
tients (3%), whereas histology revealed invasive ductal carci-
noma in 77% of all patients (n = 3,485) and invasive lobular 
tumors in  approximately 16%. Axillary dissection had been 
conducted in 1,886 patients, and 2,881 sentinel node biopsies 
had been performed, the majority (77.9%) of which were 
found to be tumor free. In total, 98% of the tested tumors 
were ER positive. Immunohistochemistry testing showed mo-
derate (2+) overexpression of HER2 in 364 samples (8% of 
Table 2. Baseline tumor characteristics of the study population and the German epidemiological patient population
Characteristic Study population, n (%) Epidemiological population, n (%)
Tumor localization (n = 4,397)
Unilateral 4,261 (96.9) 83,046 (93.0) 
Bilateral 136 (3.1) 6,271 (7.0)
Histology (n = 4,533)
Invasive ductal carcinoma 3,485 (76.9) 58,078 (65.0)
Invasive lobular carcinoma 735 (16.2) 12,525 (14.0)
Other invasive carcinoma 313 (6.9) 5,167 (5.7)
Axillary staging (n = 2,435)
Axillary dissection 1,886 (77.5) 40,393 (45.2)
SLN biopsy (n = 2,881) (n = 55,791)
SLN affected 637 (22.1) 11,817 (21.2)
SLN not affected 2,244 (77.9) 43,974 (78.8)a
Tumor grade (n = 4,533)
1 625 (13.8) 14,653 (16.4)
2 3,011 (66.4) 56,558 (63.3)
3 856 (18.9) 16,206 (18.1)
Not determined 41 (0.9) 1,863 (2.1)
Tumor stage (n = 4,533)b –
Stage 0 Tis N0 17 (0.38)
Stage IA T1 N0 1,910 (42.14)
Stage IB T0 or T1 N1 mi 71 (1.57)
Stage IIA T0 or T1 N1 407 (8.98)
T2 N0 845 (18.64)
Stage IIB T2 N1 490 (10.81)
T3 N0 46 (1.01)
Stage IIIA T0 or T1 or T2 N2 278 (6.13)
T3 N1 or N2 88 (1.94)
Stage IIIB T4 N0 or N1 or N2 72 (1.59)
Stage IIIC any T N3 183 (4.04)
Stage unknown Tx or Nx or T0 N0 126 (2.78)
ER status (n = 4,530)
ER+ 4,440 (98.0) 89,317 (100.0)
PgR status (n = 4,524)
PgR+ 4,024 (88.8) 77,122 (86.3)
HER2 status by IHC (n = 4,420)
0/1+ 3,515 (79.5) 69,179 (77.5)
2+ 364 (8.2) 8,015 (9.0)
3+ 372 (8.4) 7,365 (8.2)
Not donec 169 (3.8) 4,758 (5.3)
HER2 status by FISH/CISH (n = 873) ISH positive ISH negative ISH positive ISH negative
0/1+ 0 453 (51.8) – –
2+ 46 (5.2) 244 (27.9) 1,129 (1.2) 4,618d (5.2)
3+ 65 (7.4) 6 (0.69) – –
Not donec 0 59 (6.76) – –
aSLN negative or not documented.
bTumor staging according to TNM UICC (Union for International Cancer Control) ed 7.
cPatients for whom the HER2 status was determined but the investigator did not document the result.
dFISH/CISH tumor status was unknown for 2,268 patients.
SLN = Sentinel lymph node, pT = pathological assessment of the primary tumor, pN = pathological assessment of regional lymph nodes,  
ER = estrogen receptor, PgR = progesterone receptor, HER2 = human epidermal growth factor receptor 2, IHC = immunohistochemistry,  
FISH = fluorescent in-situ hybridization, CISH = chromogen in-situ hybridization, ISH = in-situ hybridization.
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Patient-Reported Breast Cancer Therapy and Information
The majority of the patients (82%) considered themselves to 
be compliant with the medication they were prescribed prior 
to participation in the PACT trial. Only 8% reported that 
they did not consistently take their medication; 10% of the 
patients did not respond to this question. At study start, the 
patients received a questionnaire concerning patient satisfac-
tion (EORTC IN-PATSAT32 plus questions specific to the 
antihormonal treatment). They were asked if they had had a 
say in their treatment decision, and more than half (n = 2,429) 
reported ‘good’ or ‘satisfactory’ levels of involvement. Ap-
proximately 80% of the patients (n = 3,588) said they received 
‘good’ or ‘satisfactory’ levels of information about their ther-
apy and drug effects; approximately 75% (n = 3,321) reported 
being content with the level of information they had received 
regarding side effects (table 4).
Patient-Reported Global Health Status and Quality of Life
Results from the EORTC QLQ-C30 and -BR23 functional 
scales showed that, at study start, the most positive score was 
for cognitive functioning (mean value 77.58), followed by 
physical functioning (72.89) and body image (72.15). The pa-
tients scored sexual functioning particularly negatively 
BCS had been received by 79% of the patients aged ≤ 65 
years and by 75% of the patients aged > 65 years. Mastectomy 
had been performed on 22% of the patients ≤ 65 years and on 
26% of the patients > 65 years (p = 0.0006).
Radiotherapy was planned for 85% of the patients (n = 
3,751). At study start, 19% of the patients had completed ra-
diotherapy and, for 57%, treatment was in progress or had 
not yet started; there were missing data for 9% of the patients. 
Analysis of the use of radiotherapy according to the type of 
surgery received showed that post-operative radiotherapy was 
scheduled for 95% of the patients who had undergone BCS, 
compared with 53% of the patients who had received mastec-
tomy. Reflecting the postmenopausal, hormone-sensitive na-
ture of this patient population, only 285 patients (7%) had re-
ceived neoadjuvant chemotherapy, the majority (79%, n = 
225) of whom had received combination therapy including an 
anthracycline and a taxane. Adjuvant chemotherapy was 
known to be scheduled for 38% (n = 1,682) of the patients, 
and 86% (n = 1,440) of these patients had completed their 
planned adjuvant chemotherapy at baseline (table 3). As in 
the neoadjuvant setting, the most frequently scheduled adju-
vant chemotherapy regimen was a combination of an anthra-
cycline and a taxane (56.1%).
Table 3. Prior surgery, radiotherapy and chemotherapy of the patients
Characteristic n (%)
Primary breast surgerya
Axillary lymphnodectomy 1,809 (20.3)
BCS 3,377 (38.0)
Mastectomy 1,062 (11.9)
Oncoplastic surgery 191 (2.2)
No surgery 2 (< 0.1)
Other 65 (0.8)
Sentinel lymph node biopsy 2,393 (26.9)
Neoadjuvant chemotherapy (n = 4,397)
Anthracycline-containing therapy 42 (1.0)
Anthracycline- and taxane-containing therapy 225 (5.1)
No chemotherapy scheduled 4,112 (93.5)
Other 18 (0.4)
Post-operative chemotherapy (n = 4,397)
Not scheduled 2,715 (61.8)
Scheduled 1,682 (38.3)
Completed 1,440 (32.8)
In progress/not started 99 (2.3)
Not disclosed 143 (3.3)
Scheduled post-operative chemotherapy regimens (n = 1,682)
Anthracycline-containing therapy 610 (36.3)
Anthracycline- and taxane-containing therapy 943 (56.1)
CMF 20 (1.2)
Other therapy 109 (6.5)
Post-operative radiotherapy (n = 4,397)
Not scheduled 646 (14.7)
Scheduled 3,751 (85.3)
Completed 837 (19.0)
In progress/not started 2,519 (57.3)
Not disclosed 395 (9.0)
Post-operative radiotherapy according to surgery (n = 4,333) BCS (n = 3,301)b Mastectomy (n = 1,032)b
Not scheduled 163 (4.9) 484 (46.9)
Scheduled 3,138 (95.1) 548 (53.1)
aTotal number of procedures reported = 8,899. Multiple responses permitted per patient, 57 patients received both BCS and mastectomy.
bNumber of patients receiving BCS or mastectomy (not number of procedures performed).
CMF = Cyclophosphamide, methotrexate and 5-fluorouracil; BCS = breast-conserving surgery.
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(18.41), with 1,981 (54.5%) reporting no interest in or partici-
pation in sexual activity at all (table 5). Results from the sym-
ptom scales showed that hair loss was the most significant 
symptom reported (mean value 57.98) at study start, perhaps 
related to prior chemotherapy treatment. This was followed 
by fatigue (45.41) and sleep disturbance (44.24). Nausea/ 
vomiting (10.05) and diarrhea (11.23) were considered to be 
the mildest symptoms (table 6).
Discussion
The PACT study was designed to achieve enrollment of a 
wide range of patients from across Germany. It is the first 
prospectively designed, randomized controlled study evalua-
ting therapy compliance in patients with primary breast can-
cer. PACT was designed to analyze compliance with adjuvant 
AI therapy, and factors considered to potentially influence T
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Table 5. Patients’ quality of life at start of treatment assessed via the 
EORTC QLQ-C30 and the EORTC QLQ-BR23
Endpoint Mean score
Physical functioning (n = 4,029) 72.89
Role functioning (n = 3,996) 57.70
Emotional functioning (n = 4,019) 58.93
Cognitive functioning (n = 4,025) 77.58
Social functioning (n = 4,010) 67.61
Global health status/QoL (n = 3,983) 56.70
Body image (n = 3,977) 72.15
Sexual functioning (n = 3,633) 18.41a
Sexual enjoyment (n = 1,010) 49.60
Future perspective (n = 3,984) 35.58
a1,981 patients reported no interest in or participation in sexual activity 
at all.
0 = ‘Very poor’ refers to a score of 1 in the EORTC QLQ-C30;  
100 = ‘excellent’ refers to a score of 7 in the Global health status/QoL 
and to a score of 4 for all other questions.
SD = Standard deviation, QoL = quality of life, EORTC = European 
Organization for Research and Treatment of Cancer.
Table 6. Symptom reporting by the patients at the start of treatment, as-
sessed via the EORTC QLQ-C30 and the EORTC QLQ-BR23
Symptoms Mean score
Breast symptoms (n = 3,948) 28.81
Arm symptoms (n = 3,942) 29.53
Hair loss (n = 1,780) 57.98
Fatigue (n = 4,013) 45.41
Nausea and vomiting (n = 4,007) 10.05
Pain (n = 4,023) 32.71
Dyspnea (n = 3,962) 28.57
Sleep disturbances (n = 3,994) 44.24
Loss of appetite (n = 4,017) 20.92a
Constipation (n = 3,983) 18.08a
Diarrhea (n = 3,979) 11.23a
aThe majority of patients were not symptomatic in this category.
0 = ‘No symptoms’ refers to a score of 1 in this questionnaire;  
100 = ‘very strong symptoms’ refers to a score of 4 for all symptoms  
in the EORTC QLQ-30.
EORTC = European Organization for Research and Treatment  
of Cancer.
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ahead of BCS [25]. In Italy, while the Italian Association of 
Medical Oncology (AIOM) guidelines recommend BCS for 
patients with stage I–II breast cancer, patient and tumor char-
acteristics, patient preference and technical reasons all limit 
adherence to this guidance [26]. It is likely that these external 
pressures vary across Europe, restricting the ability of physi-
cians to strictly follow treatment recommendations.
A previous study found that patients of older age (> 60 
years), those who had not attended further education and/or 
those without internet access were less likely to have been 
 involved in the decision regarding endocrine treatment for 
breast cancer [27]. This puts them at increased risk for poor 
compliance and makes them particularly suitable for the 
PACT program. Indeed, over 70% (n = 3,107) of the patients 
randomized in the PACT study were > 60 years old.
The baseline data gathered in PACT provided the oppor-
tunity to understand patient perceptions about medication 
taking and compliance prior to participation in the trial. 
 Approximately 80% of the patients reported that they 
 ‘always’ took their medicine. Prospective data suggest that, 
at 24 months, 82% of patients are still compliant with their 
AI treatment [28]. In comparison, retrospective data suggest 
that 19–28% of patients may be non-compliant with their 
AI medication at 12 months (not taking at least 80%), with 
this figure rising to 32–50% of patients at 3 years [29]. It will 
be interesting to see whether the compliance results from 
PACT concur with the patients’ self-reported compliance, and 
with previously reported data on this topic. While the major-
ity of the patients reported that their involvement in the treat-
ment decision and information about side effects had been 
‘good’ or ‘satisfactory’, 20–25% of the patients were unsatis-
fied. If this level of dissatisfaction is translated into comp-
liance behavior in the study, a substantial proportion of pati-
ents may not be taking their medication correctly. The PACT 
study is investigating whether EM could improve patients’ 
 understanding about their treatment and ultimately could 
 improve compliance.
While all attempts were made to enroll patients throughout 
Germany, we do not know how representative our sample is 
compared with the entire German breast cancer population. 
Additionally, patients who are able to and do consent to parti-
cipate in clinical trials are a self-selected population. It has 
been previously reported that patients who join clinical trials 
are well motivated and may therefore be more likely to be 
compliant with their medication [30]. To answer this question, 
we consulted the epidemiological patient population from the 
West German Breast Center (WBC). This center compiles 
data on the primary treatment of breast cancer from 220 Ger-
man breast centers, which collectively represent approxi-
mately two-thirds of the nationwide breast cancer cases. This 
in formation is used for benchmarking purposes, and the data 
on women with postmenopausal ER-positive breast cancer 
give a useful reference point to assess whether the PACT 
population was representative of the overall German breast 
compliance such as concurrent medications and attitudes to-
wards treatment were also collected. The number of patients 
enrolled in PACT generated the largest database compiled to 
date in a single country to comprise a homogeneous cohort of 
postmenopausal patients with ER-positive early breast can-
cer. The database was interrogated to analyze patient demo-
graphic and baseline disease characteristics as well as patterns 
of prior treatment selection and quality-of-life endpoints.
The patients in the PACT study met clear inclusion/exclu-
sion criteria and were recruited throughout Germany, from 
both research units and centers that do not frequently partici-
pate in clinical studies, providing a much more heterogeneous 
population than if patients had been recruited from a single 
center or region. As they were preselected for AI therapy 
 before study enrollment (non-interventional design) and had 
received or were scheduled for prior and concomitant treat-
ments before enrollment, we believe these patients are truly 
representative of current treatment practices in Germany.
Patient demographics were similar between PACT and the 
phase III international ATAC trial with anastrozole [20] in 
terms of median patient age (65.5 vs. 64.3 years, respectively), 
mean height (164 vs. 161 cm), mean weight (73 vs. 71 kg) and 
mean BMI (27.2 vs. 27.7 kg/m2). Therefore, this suggests that 
patients in the PACT study are representative of a general 
early breast cancer population and that its findings may be 
 applicable beyond Germany.
The majority of the patients in the PACT study were 
 married, of retirement age and spent much of their time at 
home. These factors have been associated with good compli-
ance levels [12, 17, 18], suggesting that the patients in PACT 
may have been more predisposed to compliance with taking 
medication than other populations.
Significantly more patients had undergone mastectomy in 
the more elderly age group than in the younger patient group. 
This finding has been reported previously [19] despite similar 
proportions of older (≥ 80 years) and younger (67–79 years) 
women reporting concerns about physical appearance: 
27% and 32%, respectively (p = 0.25). Furthermore, data 
have shown that a greater number of elderly patients (aged 
≥ 70 years) given the choice select BCS over mastectomy [20]. 
It is possible that clinicians are selecting mastectomy over 
BCS in more elderly patients to minimize the need for radio-
therapy, which is less well tolerated by these patients. This 
 option may appear preferable for patients who have concerns 
about the safety or efficacy of radiotherapy versus surgery 
[21, 22], and such practices have been reported previously in 
the Tamoxifen Exemestane Adjuvant Multinational (TEAM) 
and Intergroup Exemestane Study (IES) trials [23, 24]. In the 
overall PACT population, the majority of patients received 
BCS. However, data collected from other European studies 
indicate differences in surgical treatment patterns across the 
continent. In a Netherlands-specific sub-analysis of the 
TEAM study, mastectomy was the most frequently utilized 
surgical option for patients with early invasive breast cancer, 
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was developed, which is ongoing in Europe, Australia and 
South America [28]. The data from this study will provide a 
more international perspective on the PACT data and pro-
vide a broader database of the treatment of postmenopausal 
patients with early breast cancer.
In summary, PACT is the first clinical trial of its kind, 
 designed to prospectively evaluate compliance with an AI 
(anastrozole) in breast cancer. This study has generated 
the largest homogeneous database to date of prospectively 
 collected information on patients with early breast cancer, 
 including treatment practices and patient attitudes, in a 
single country. We consider our population to be representa-
tive of patients throughout Germany and, therefore, the re-
sults of the PACT study will raise relevant concerns for 
physicians.
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cancer population. While comparable data are not available 
for all parameters, the patient disease characteristics were 
similar across both populations (written communication, 
 Harbeck and West German Breast Cancer Center 2012). Uni-
lateral disease was most frequently observed and the majority 
of patients had a grade 2 tumor. Invasive ductal carcinoma 
was the most frequently observed histology in both groups, 
and the majority of patients had no sentinel lymph node 
 involvement (77.9% vs. 78.8%). FISH/CISH analysis of 
 patients with moderate overexpression of HER2 was more 
frequently used by the PACT investigators than by the collec-
tion of German breast centers (33% vs. 6.4%). Overall, this 
indicates that, despite the implementation of patient inclusion 
criteria, the PACT cohort appears to provide a fair represen-
tation of the overall German breast cancer population.
There are several limitations to this baseline analysis that 
can be attributed to the nature of its non-interventional 
 design. Over 4,900 patients were enrolled across 109 breast 
cancer centers and clinics. As such, inconsistencies in the 
 classification and documentation of patient treatment by 
 physicians were expected and indeed observed. In particular, 
despite being mutually exclusive within the primary surgery 
classification, 57 patients received both BCS and mastectomy. 
These 57 patients may have undergone BCS and subsequent 
mastectomy, as multiple procedures were permitted per pati-
ent. However, this could also have been the result of diffe-
rences in the interpretation of the CRF where physicians 
 recorded partial mastectomies as both BCS and mastectomy, 
or due to irregularities in patient notes. A further limitation 
was the use of patient questionnaires to collect information on 
certain parameters (e.g. concomitant medication and conditi-
ons). This led to a large amount of missing data, and the 
 results derived using this methodology may underestimate the 
actual patient demographics.
Following the initiation of PACT, a similar international 
trial (Compliance of ARomatase Inhibitors AssessmenT In 
Daily practice through Educational approach (CARIATIDE)) 
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